AngelMD’s Catalyst I LP announced today that it has invested in Artoss, Inc. Artoss is a bone biologic company focused on improving bone graft technology through a combination of nanotechnology and biology. This is Angel®’s second investment in the company, following a combined syndicate round in Q1 2016.
There are numerous risks with traditional bone grafts, including rejection of the grafting material and infection of the donated bone. As noted by the National Center for Biotechnology Information, graft success is further complicated by unacceptable processing techniques that can destroy the structure and osteo-inductive capacity of the graft material.
More recent advances in the field have been based on novel graft materials, such as Artoss’ NanoBone technology. NanoBone improves existing processes by using hydroxyapatite nanocrystals (the main structural element of naturally occurring bone) which are suspended in the silica gel matrix. These crystals closely mimic the hydroxyapatite found in human bone and are 100,000 times smaller than the bioceramic particles found in other grafting treatments. Their smaller size leads to higher acceptance rates and better end results for the patient.
NanoBone has proven to be clinically effective in Europe, where the company has been operating for more than 10 years. Artoss is bringing the full line of NanoBone products to the United States after approval of FDA 510(k) has been granted. In addition, the company’s products have recently been approved for purchase by the United States Department of Defense under a Defense Acquisition Purchase Agreement with the Prime Vendor, Owens & Minor.
Most recently, Artoss announced its NanoBone QD Bone Graft product, enabling quick delivery of NanoBone SBX Putty via an applicator that facilitates controlled and accurate use in a cost-effective system. The product will be on display at the 2017 North American Spine Society NASS Conference in Orlando from 25 to 28 October 2017.
Charlie Emley, Managing Partner of the Catalyst I Fund, initially joins the Board of Directors of Artoss as a Board Observer, lending his extensive management and investing expertise to support Artoss, Inc. Managing Team
“As revenue continues to grow and the visibility and interest of the industry increases, we felt that this was the ideal time to add support to the company as it moves to the next level. I look forward to working with the founders and their German partners, all seasoned veterans with a record of success,” said Charlie Emley.
“The contacts, feedback and capital we received from the AngelMD community helped us achieve some very early wins. With the debut of our new NanoBone QD Bone Graft at the North American Spine Society meeting this week, the capital of their Catalyst Venture Fund, and the expertise of Charlie Emley, we are on the verge of a successful 2018. “James Cassidy, PhD, Artoss, Inc. Co-Founders
###########################
About Angel®
Angel® is an investment and networking platform that connects innovative medical startups, physicians, investors and industry partners. Leading physicians from all over the U.S. joined AngelMD to help source, evaluate and advise biotech, medical device, and healthcare technology companies. Visit http://www for more information. The Angelms Oh, co
Artoss, Inc.
Inc, Artoss It is a leading bone biologic company, focused on nanobiology Nanobiology is the intersection between nanotechnology and biology. Artoss scientists apply their knowledge of physics and biology to the creation of new nanostructured bone repair biomaterials. Visit artossinc for more information. Come on,
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Artoss/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
